NCT00864071View on ClinicalTrials.gov

A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Healthy
Interventions
DRUG

Griseofulvin 125 mg/5 mL Suspension, single dose

A: Experimental Subjects received Alpharma formulated products under fasting conditions

DRUG

Grifulvin V® 125 mg/5 mL Suspension, single dose

B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions

Trial Locations (1)

M1L 4S4 / M1L 4R6

Biovail Contract Research (A Division of Biovail Corporation), Toronto

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00864071 - A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions | Biotech Hunter | Biotech Hunter